Literature DB >> 6435188

The analysis of arachidonic acid metabolites in normal, uninvolved and lesional psoriatic skin.

R M Barr, E Wong, A I Mallet, L A Olins, M W Greaves.   

Abstract

Collection of exudate from suction bullae is a commonly used method for sampling human skin for mediator analysis. It is satisfactory on skin of normal structure but is unreliable on lesional psoriatic skin in which there are major structural changes and excessive scaling. Collection of exudates from abraded sites was found to be a suitable alternative method for psoriatic skin. Arachidonic acid and 12-HETE, but not PGE2, were significantly higher in exudate from abraded lesional psoriatic skin (494 +/- 88, 45.9 +/- 4.2 and 9.6 +/- 1.8 ng/ml respectively, mean +/- sem, n = 5) compared to uninvolved skin (154 + 38, 18.5 + 5.1 and 7.7 + 1.9 ng/ml) or skin of normal volunteers (119 +/- 37, 14.5 +/- 6.7 and 4.5 +/- 1.6 ng/ml, n = 7) which were similar. The coefficient of variation for exudate collection and mediator analysis was usually less than 55%. The analysis of lipoxygenase and cyclooxygenase products was simplified by the use of chlorobutane to extract preferentially arachidonic acid and HETEs from neutral aqueous solutions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6435188     DOI: 10.1016/0090-6980(84)90113-8

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  20 in total

1.  Metabolism of exogenous arachidonic acid by polymorphonuclear leukocytes from psoriatic patients.

Authors:  J Solá; L Vila; L Puig; J M de Moragas
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

2.  Interleukin-1 alpha gene-transcription in murine keratinocytes is inhibited by HSV-1 infection.

Authors:  C Enk; E Sprecher; Y Becker
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

3.  Biochemical and pharmacological properties of a new topical anti-inflammatory compound, 9-phenylnonanohydroxamic acid (BMY 30094).

Authors:  K M Tramposch; F C Zusi; S A Marathe; P L Stanley; X Nair; S A Steiner; J W Quigley
Journal:  Agents Actions       Date:  1990-06

4.  The release of prostaglandin D2 from human skin in vivo and in vitro during immediate allergic reactions.

Authors:  R M Barr; O Koro; D M Francis; A K Black; T Numata; M W Greaves
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

5.  Psoriatic skin lesions contain a novel lipid neutrophil chemokinetic compound which is distinct from known chemoattractant eicosanoids.

Authors:  R D Camp; F M Cunningham; N J Fincham; M W Greaves; A Kobza Black; A I Mallet; P M Woollard
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

6.  The design and synthesis of second generation leukotriene B4 (LTB4) receptor antagonists related to SC-41930.

Authors:  T D Penning; S W Djuric; S H Docter; S S Yu; D Spangler; C P Anglin; D J Fretland; J F Kachur; R H Keith; B S Tsai
Journal:  Agents Actions       Date:  1993

7.  The effect of etretinate on the cyclo-oxygenase and lipoxygenase products of arachidonic acid metabolism in psoriatic skin.

Authors:  E Wong; R M Barr; S D Brain; M W Greaves; L A Olins; A I Mallet
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

8.  Topical steroid treatment reduces arachidonic acid and leukotriene B4 in lesional skin of psoriasis.

Authors:  E Wong; R M Barr; F M Cunningham; K Mistry; P M Woollard; A I Mallet; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

9.  Monohydroxy fatty acids esterified to phospholipids are decreased in lesional psoriatic skin.

Authors:  B Grøn; L Iversen; V Ziboh; K Kragballe
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

10.  Platelet activating factor (PAF) and lyso-PAF in psoriasis.

Authors:  M R Judge; R M Barr; A I Mallet; F Courtney; A Kobza Black; M W Greaves
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.